Livongo Health (NASDAQ:LVGO) hit a new 52-week high during trading on Monday . The company traded as high as $81.16 and last traded at $79.88, with a volume of 1290794 shares changing hands. The stock had previously closed at $72.81.
A number of brokerages have recently commented on LVGO. Cowen increased their price objective on Livongo Health from $69.00 to $88.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. KeyCorp increased their target price on Livongo Health from $85.00 to $105.00 in a research note on Tuesday. Piper Sandler increased their target price on Livongo Health from $42.00 to $55.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Stifel Nicolaus assumed coverage on Livongo Health in a research note on Thursday, March 19th. They set a “buy” rating and a $30.00 target price for the company. Finally, Guggenheim assumed coverage on Livongo Health in a research note on Thursday, April 23rd. They set a “buy” rating and a $46.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Livongo Health currently has a consensus rating of “Buy” and an average target price of $62.71.
The stock has a fifty day moving average price of $64.75 and a 200-day moving average price of $39.15. The firm has a market capitalization of $7.59 billion and a price-to-earnings ratio of -81.53.
Livongo Health (NASDAQ:LVGO) last issued its earnings results on Wednesday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.07. Livongo Health had a negative return on equity of 11.81% and a negative net margin of 22.05%. The business had revenue of $68.80 million during the quarter, compared to analysts’ expectations of $66.11 million. The firm’s revenue was up 114.3% on a year-over-year basis. As a group, equities research analysts expect that Livongo Health will post -0.37 earnings per share for the current fiscal year.
In related news, President Jennifer Schneider sold 6,700 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $58.98, for a total transaction of $395,166.00. Following the completion of the sale, the president now directly owns 229,489 shares of the company’s stock, valued at approximately $13,535,261.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hemant Taneja sold 300,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $52.88, for a total value of $15,864,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 515,009 shares of company stock valued at $28,872,089. 13.00% of the stock is currently owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in LVGO. State Street Corp increased its holdings in Livongo Health by 22.7% during the 4th quarter. State Street Corp now owns 259,487 shares of the company’s stock valued at $6,503,000 after purchasing an additional 47,971 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Livongo Health in the 4th quarter valued at $207,000. Charles Schwab Investment Management Inc. increased its stake in shares of Livongo Health by 4.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 84,753 shares of the company’s stock valued at $2,124,000 after buying an additional 3,788 shares during the period. Bank of Montreal Can acquired a new stake in shares of Livongo Health in the 4th quarter valued at $47,000. Finally, Schroder Investment Management Group increased its stake in shares of Livongo Health by 78.5% in the 4th quarter. Schroder Investment Management Group now owns 45,287 shares of the company’s stock valued at $1,135,000 after buying an additional 19,911 shares during the period. 38.70% of the stock is owned by hedge funds and other institutional investors.
Livongo Health Company Profile (NASDAQ:LVGO)
Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.
Featured Article: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.